NCT07205783Enrolling by invitation
Open Radical Prostatectomy Versus Curative Radiotherapy for Treatment of Organ Confined Prostate Cancer (Retrospective Comparative Study)
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
In the last few decades not only the diagnosis but also the treatment options for prostate cancer have changed significantly. During this time the surgical procedure of open radical prostatectomy was substantially modified(1,2) and is nowadays considered a safe procedure providing high cancer control rates with low morbidity.(3) The main goal of radical prostatectomy regardless of the approach remains the eradication of cancer while preserving pelvic organ function,whenever possible.(4)
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 26 Sept 2025
- Start date
- 14 Sept 2022
- Primary completion date
- 14 Sept 2026
- Lead sponsor
- Sohag University
- Diseases
- Prostate cancer
- NCT number
- NCT07205783
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 14 Sept 2022 to the primary completion date, 14 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- coagulopathy. Pulmonary diseases metastatic tumor
Who the study is looking for
- Cancer prostate: confirmed by prostate biopsy Cancer stage: T2,T3
Age in the registry: 40 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.